

BRCA2 Polyclonal Antibody

Catalog No: YT0520

Reactivity: Human;Rat

Applications: IHC;IF;ELISA

Target: BRCA2

Fields: >>Homologous recombination;>>Fanconi anemia pathway;>>Pathways in

cancer;>>Pancreatic cancer;>>Breast cancer

Gene Name: BRCA2

Protein Name: Breast cancer type 2 susceptibility protein

P51587

P97929

Human Gene Id: 675

Human Swiss Prot

No:

Mouse Swiss Prot

No:

Rat Swiss Prot No: 035923

Immunogen: The antiserum was produced against synthesized peptide derived from human

BRCA2. AA range:31-80

Specificity: BRCA2 Polyclonal Antibody detects endogenous levels of BRCA2 protein.

Formulation : Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Source: Polyclonal, Rabbit, IgG

Dilution: IHC 1:100 - 1:300. ELISA: 1:20000.. IF 1:50-200

Purification: The antibody was affinity-purified from rabbit antiserum by affinity-

chromatography using epitope-specific immunogen.

Concentration: 1 mg/ml

1/3



Storage Stability: -15°C to -25°C/1 year(Do not lower than -25°C)

Molecularweight: 384kD

Cell Pathway : Homologous recombination; Pathways in cancer; Pancreatic cancer;

Background: Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime

risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele. [provided by

RefSeq, Dec 2008],

Function: disease:Defects in BRCA2 are a cause of genetic susceptibility to breast cancer

(BC) [MIM:612555, 114480]; also called susceptibility to familial breast-ovarian cancer type 2 (BROVCA2). BC is an extremely common malignancy, affecting one in eight women during their lifetime. A positive family history has been identified as major contributor to risk of development of the disease, and this link is striking for early-onset breast cancer. Mutations in BRCA2 are thought to be responsible for some inherited breast cancer. It is linked with male breast cancer., disease:Defects in BRCA2 are the cause of Fanconi anemia complementation group D type 1 (FANCD1) [MIM:605724]. Fanconi anemia [MIM:227650] is an autosomal recessive disorder affecting all bone marrow

elements and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes.,function:Involved in double-strand

Subcellular

Nucleus . Cytoplasm, cytoskeleton, microtubule organizing center, centrosome .


Colocalizes with ERCC5/XPG to nuclear foci following DNA replication stress. .

Expression: Highest levels of expression in breast and thymus, with slightly lower levels in


lung, ovary and spleen.

Products Images

2/3



Immunohistochemical analysis of paraffin-embedded Human brain. Antibody was diluted at 1:100(4° overnight). High-pressure and temperature Tris-EDTA,pH8.0 was used for antigen retrieval. Negetive contrl (right) obtaned from antibody was pre-absorbed by immunogen peptide.



Immunohistochemistry analysis of paraffin-embedded human brain tissue, using BRCA2 Antibody. The picture on the right is blocked with the synthesized peptide.